Drugs / S-531011
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07591597 | May 2026 → Jul 2027 expected | colorectal cancer | National Cancer Center Hospital East | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05101070 | May 2022 → May 2028 expected | cancer | Shionogi | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07720115 | Aug → Sep 2026 | colorectal cancer | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-531011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07591597 ↗ |
| Route | Intravenous | “Administered by intravenous infusion” NCT05101070 ↗ |